SynthesisFrontiers in immunology2025
Changes in the
Synthesis in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Autoimmune diseases have different pathogenic mechanisms but share underlying patterns of gut microbiome perturbation and intestinal barrier dysfunction. Recent evidence suggests that an arthritogenic strain of Objective: To evaluate the changes of Methods: Four databases, including PubMed, Cochrane, Web of Science, and Embase, were searched up to June 17, 2025, to identify studies that detected Study selection: We included articles that addressed both autoimmune diseases without intervention and the detection of Quality assessment: We used the Newcastle-Ottawa Scale (NOS) to independently assess the methodological quality of the case-control studies. The Journal of Biomedical Informatics (JBI) critical appraisal checklists were utilized to assess the quality and risk of bias in cross-sectional studies. Results: Twelve studies were included. These studies were conducted in four different countries and included a total of 1,792 participants (patients with autoimmune disease and healthy controls). Our meta-analysis results indicate that, compared with healthy controls, most patients with autoimmune diseases included in the study had lower levels of Conclusion: The abundance of Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024543767, identifier CRD42024543767.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.